Early Clinical Outcomes Of A New Enhanced Monofocal Intraocular Lens (Emv, Rayner)

Published 2022 - 40th Congress of the ESCRS

Reference: PO186 | Type: Free paper | DOI: 10.82333/qdny-2740

Authors: Shafiq Rehman* ¹ , Alex Shortt ² , Amir Hamid ² , Nabila Jones ¹ , Andrew Turnbull ² , Irene Sisó-Fuertes ¹ , Clare ODonnell ¹

¹Eye Sciences,Optegra Eye Health Care,Manchester,United Kingdom, ²Eye Sciences,Optegra Eye Health Care,London,United Kingdom

Purpose

To report the emerging clinical outcomes including complications, post-operative visual acuity, and refractive outcome data after small incision phacoemulsification surgery with implantation of Rayner RayOne EMV extended depth of focus intraocular lens.

Setting

Optegra Eye Health Care

Methods

A retrospective audit of the clinical outcomes of 36 consecutive cataract patients (mean age 66+/-10 years) following implantation of an EMV IOL (Rayner, Worthing, UK) was carried out between August 2021 and February 2022. Either a targeted monovision or emmetropic distance outcome was planned. Data were recorded in an electronic medical record at up to 3 months post-operatively. Procedures were excluded from the visual analysis if they had reasons for guarded visual prognosis such as amblyopic cases or AMD.

Results

Emerging post-operative data from 66 eyes from 36 patients were included. 89% of distance targeted eyes achieved UDVA 20/40 or better and 51% achieved UDVA 20/20 or better. 89% of eyes had a SEQ within ±1.00D of predicted target. 100% of patients achieved 20/40 or better, 69% achieved 20/20 and 100% of patients targeted for a monovision outcome achieved N8 or better binocularly.

Conclusions

Our early data show that the emerging clinical outcomes and patient satisfaction appear favourable for this cohort overall. Data collection and analysis are ongoing and final follow up data will be reported in due course.